



Harnessing the power of big data in prostate cancer research – Data access and sources in the PIONEER project

Authors: Susan Evans-Axelsson^a, Thomas Abbott^b, Louise Fullwood^c, Maxim Moinat^d, Carl Steinbeisser^e, Alex Asiimwe^e, Muhammad Imran Omar^f, James N'Dow^g, **Anders Bjartell^a** and PIONEER Consortium*
Affiliations: a. Lund University, b. Astellas, c. Pinsent Masons, d. The Hyve, e. Bayer AG, f. University of Aberdeen, g. European Association of Urology

About PIONEER

Prostate Cancer DiagnOsis and TreatmeNt Enhancement through
the Power of Big Data in EuRope

The European Network of
Excellence for Big Data in
Prostate Cancer

- An IMI2 funded pan-European public private partnership consisting of 32 stakeholders from across 9 countries.
- Launched in May 2018 PIONEER brings together all relevant stakeholders in the field of prostate cancer research as well as clinical and social care.
- Five year (2018-2023) 12 M€ program.

PIONEER's goal & Key Aspects

To ensure the optimal care for all European men diagnosed with prostate cancer by unlocking the potential of big data and big data analytics.




Work Package 3

Data Access and sources

Identify, approach and negotiate appropriate data sharing agreements with a variety of holders of high-quality, real-life prostate cancer-based datasets across European and non-European patient populations.

Methods and Materials

To effectively tackle WP3 work plan, subgroups were formed:




Data sources

Type of data contributors that may be approached by PIONEER for participation: Academics, Large clinical practices and medical centres, Life sciences industry, Data aggregators, Payers/governments

EU-based data sources from:




Non-EU data sources from:



Individual databases are built on: Retrospective and Prospective single institute, Prospective multi-institute, Population-based cohorts, Randomised control trial cohorts, Retrospective and prospective multi-institutional

Data sharing models

- PIONEER will utilise the Federated (remote data) and Central (imported data) data sharing models
- The data sharer can determine which model is best for them



Results

- PIONEER has over 60 EU and non-EU potential data sources identified
- WP3 and WP8 (legal, ethics and governance) have established two standardised DSA (Data sharing agreement) templates to be used with data contributors.
- As of September 2019 datasets:
 - **ERSPC Rotterdam and PRIAS (Europe)** datasets are in the process of being mapped to OMOP (Federated sharing model)
 - **Malmö Diet and Cancer/Malmö Preventative Medicine** (Sweden) has chosen to use the Central sharing model.
- Access to clinical trial datasets from industry partners, in most cases, will be provided through **Project DataSphere**.
- Negotiations are underway for access to databases from Australia/New Zealand, Germany, Finland, the UK, the Netherlands, Denmark, Norway and the USA.

Conclusion

PIONEER has infinite potential thanks to its size and content.

By applying big data analytics and developing a data platform of unparalleled scale, quality and diversity, PIONEER will be able to answer questions about prostate cancer in a new way that will empower meaningful improvement in clinical practice, prostate cancer disease-related outcomes and health economic outcomes across the European healthcare landscape.

How to contribute

PIONEER coordinator: James N'Dow, EAU
✉ j.ndow@abdn.ac.uk

PIONEER Deputy coordinator: Anders Bjartell
✉ Anders.Bjartell@med.lu.se

WP3 coordinator: Susan Evans-Axelsson, PhD
✉ Susan.Evans-Axelsson@med.lu.se



www.prostate-pioneer.eu
@ProstatePioneer